News & Updates

Deaths from C. difficile higher in women, White patients

Despite advances in infection control and antimicrobial stewardship, mortality from Clostridioides difficile (C. difficile) enterocolitis continues to disproportionately affect certain populations in the US, according to an analysis of the CDC WONDER database presented at IDWeek 2025.

HFrEF outcomes due to Chagas disease no better with sacubitril/valsartan vs enalapril

In the treatment of patients with heart failure with reduced ejection fraction (HFrEF) secondary to Chagas disease, the use of sacubitril/valsartan does not appear to lead to improvements in clinical outcomes compared with enalapril, according to a study.

Laughing gas touted as rapid-acting antidepressant in meta-analysis

Administration of nitrous oxide (N2O) appears to alleviate depressive symptoms as quickly as 2 h, according to a meta-analysis.

Sedentary behaviour tied to arterial stiffness in older adults

A sedentary behaviour appears to contribute to increased arterial stiffness among older adults, suggests a recent study.

Mindfulness-based interventions may ease burnout among HCPs

Mindfulness-based interventions are helpful in reducing burnout among nurses and midwives, as well as among a mixture of healthcare professionals (HCPs), but professional coaching appears more beneficial among physicians, especially when done for more than 4 weeks, suggests a study.

Arterial stiffness linked to small-, large-fiber neuropathy

A recent study has shown the association of greater arterial stiffening with both ocular (small) and peripheral (large) fiber neuropathies.

Systemic vascular resistance higher in people with family history of hypertension

Individuals with a family history of hypertension show increased central and peripheral blood pressure (BP) potentially due to higher systemic vascular resistance (SVR), according to a study. On the other hand, large artery stiffness is not elevated.

Changing the Narrative: Basics, Breakthroughs and Breaking Barriers in Treating Cardiovascular Diseases (CVDs)

Inebilizumab MITIGATEs flares in IgG4-RD with pancreatic, hepatobiliary involvement

The post hoc subgroup analysis of the phase III MITIGATE trial shows the benefit of the humanized monoclonal anti-CD19 antibody inebilizumab in adults with IgG4-related disease (IgG4-RD) with pancreas, bile duct, and liver involvement at baseline.